data thus indicating the potential of miR-21, miR-143 and miR-181a as a novel diagnostic or prognostic biomarker for non small cell lung cancer.

Our findings demonstrate that miR-181a expression in lung adenocarcinoma is associated with epithelial-mesenchymal transition progression

Investigated RNA-binding region-containing protein 1 (RNPC1) action on signal pathways and disease progression in lung cancer samples and cells. Found RNPC1 acts to downregulate the miR-181a mediated inhibition of cancer susceptibility 2 (CASC2) expression in lung cancer. Results show RNPC1 inhibits NSCLC progression in a miR-181a/CASC2 axis-dependent manner.

miR-181 may be a novel and important regulator of cisplatin-resistant non-small cell lung cancer by serving a role in the regulation of apoptosis, as an established rate-limiting miRNA target.